Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | OXTR | P30559 | 1/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.32 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.32 |
| ▸ | ITGAL | P20701 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL292788 | 0.76 | MAOA (0.50) | MAOAMAOBGAANPSR1NPC1 | |
| SCHEMBL30356272 | 0.76 | MAOA (0.50) | MAOAMAOBGAANPSR1NPC1 | |
| SCHEMBL11391339 | 0.74 | MAOA (0.48) | MAOAMAOBGAANPSR1NPC1 | |
| SCHEMBL1862899 | 0.74 | MAOA (0.48) | MAOAMAOBGAANPSR1NPC1 | |
| SCHEMBL57273 | 0.74 | MAOA (0.48) | MAOAMAOBGAANPSR1NPC1 | |
| SCHEMBL753891 | 0.74 | MAOA (0.48) | MAOAMAOBGAANPSR1NPC1 | |
| SCHEMBL2006248 | 0.74 | MAOA (0.48) | MAOAMAOBGAANPSR1NPC1 | |
| SCHEMBL1939933 | 0.74 | MAOA (0.48) | MAOAMAOBGAANPSR1NPC1 | |
| SCHEMBL758245 | 0.74 | MAOA (0.48) | MAOAMAOBGAANPSR1NPC1 | |
| SCHEMBL30140866 | 0.74 | MAOA (0.48) | MAOAMAOBGAANPSR1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6617281-B1 | Substituted acylamino phenyl uracils | BAYER AKTIENGESELLSCHAFT (DE) | 2003-09-09 | — | — | US | claimed |
| EP-1095028-A1 | SUBSTITUTED ACYLAMINO PHENYL URACILS | BAYER AG (DE) | 2001-05-02 | — | — | EP | claimed |
| WO-2000002867-A1 | SUBSTITUTED ACYLAMINO PHENYL URACILS | BAYER AKTIENGESELLSCHAFT (DE) | 2000-01-20 | — | — | WO | claimed |
| EP-3131897-B1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME (US) | 2022-06-15 | — | — | EP | disclosed |
| EP-3131896-B1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME (US) | 2019-01-30 | — | — | EP | disclosed |
| US-9969724-B2 | Factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9808445-B2 | Factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170129880-A1 | FACTOR IXa INHIBITORS | MERCK SHARP & DOHME LLC | 2017-05-11 | — | — | US | disclosed |
| EP-3131896-A1 | FACTOR IXA INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-02-22 | — | — | EP | disclosed |
| EP-3131897-A1 | FACTOR IXA INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-02-22 | — | — | EP | disclosed |
| US-20170027916-A1 | FACTOR IXa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-02-02 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| CN-1193020-C | Process for preparing amic acid esters | IHARA CHEMICAL IND CO (JP) | 2005-03-16 | — | — | CN | disclosed |
| US-6617281-B1 | Substituted acylamino phenyl uracils | BAYER AKTIENGESELLSCHAFT (DE) | 2003-09-09 | — | — | US | disclosed |
| US-6576765-B2 | Process for preparing amic acid esters | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2003-06-10 | — | — | US | disclosed |
| US-20030032667-A1 | PROCESS FOR PREPARING AMIC ACID ESTERS | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2003-02-13 | — | — | US | disclosed |
| CN-1366523-A | Process for preparing amic acid esters | IHARA CHEMICAL IND CO (JP) | 2002-08-28 | — | — | CN | disclosed |
| EP-1182199-A1 | PROCESS FOR PREPARING AMIC ACID ESTERS | IHARA CHEMICAL INDUSTRY Co., Ltd. (JP) | 2002-02-27 | — | — | EP | disclosed |
| EP-1095028-A1 | SUBSTITUTED ACYLAMINO PHENYL URACILS | BAYER AG (DE) | 2001-05-02 | — | — | EP | disclosed |
| WO-2000002867-A1 | SUBSTITUTED ACYLAMINO PHENYL URACILS | BAYER AKTIENGESELLSCHAFT (DE) | 2000-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129880-A1 | FACTOR IXa INHIBITORS | F9, F12, TFPI | MAOA 116/4885MAOB 250/4885GAA 210/4885 |
| US-20170027916-A1 | FACTOR IXa INHIBITORS | F9, F12, TFPI | MAOA 116/4885MAOB 250/4885GAA 210/4885 |
| US-20030032667-A1 | PROCESS FOR PREPARING AMIC ACID ESTERS | MCCC2, EMC1, GANC | MAOA 656/4885MAOB 779/4885GAA 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.